Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros












Intervalo de año de publicación
1.
Vet Sci ; 11(8)2024 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-39195818

RESUMEN

OBJECTIVE: Canine cutaneous mast cell tumors (cMCTs) have variable rates of recurrence and metastasis. We evaluated how various prognostic factors affect survival, recurrence, and metastasis in dogs with cMCT who underwent surgery and vinblastine chemotherapy. ANIMALS: 90 dogs with cMCT treated with surgery and vinblastine at a veterinary referral institution were included. METHODS: Medical records were retrospectively reviewed. Prognostic factors were evaluated. RESULTS: Most dogs (94%) had grade 2 or 3 cMCTs. Neoadjuvant vinblastine was used in 18 dogs, and none progressed locally before surgery. The use of neoadjuvant vinblastine was associated with a higher chance of local recurrence (p = 0.03) but not survival. Shorter survival times were found for tumors that were high-grade (p < 0.001), grade 3 (p < 0.001), or a MC of >5 (p < 0.001). Dogs with grade 2 tumors that were low-grade lived longer than those with high-grade tumors (p < 0.001). Histologic tumor-free margins and the ability to achieve local tumor control were not associated with outcome. CLINICAL RELEVANCE: Both grading systems and MC were prognostic for survival in this population of dogs, supporting the need for the standard reporting of histopathologic findings. Neoadjuvant chemotherapy can be effective in downsizing cMCTs but does not influence survival. These findings are consistent with previous publications, showing the benefits of a more modern population of patients, surgical treatments, and histopathologic assessments.

2.
Vet Pathol ; : 3009858241240443, 2024 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-38577816

RESUMEN

Histologic grading of canine cutaneous mast cell tumors (cMCTs) has prognostic and therapeutic implications, yet validation for subcutaneous MCTs (scMCTs) is lacking. For scMCTs with or without dermal invasion, determining their biological behavior remains poorly standardized and sometimes sparks controversy. This prospective study aimed to assess the prognostic utility of the 2-tier histologic grading system in MCTs with different growth models (GMs) and explore the prognostic impact of the GM itself. We assessed 6 histologic GM categories: solely cMCT (C-SC0), cMCT with superficial (C-SC1) or deep subcutaneous (C-SC2) involvement, solely scMCT (SC-C0), and scMCT with deep (SC-C1) or superficial (SC-C2) infiltration of the dermis. Ninety-one MCTs from 76 dogs undergoing excision and regional/sentinel lymphadenectomy were examined. GM classification identified 11 (12%) C-SC0 tumors, 12 (13%) C-SC1, 15 (16%) C-SC2, 21 (23%) SC-C0, 15 (16%) SC-C1, and 17 (19%) SC-C2. Mitotic count, 2-tier grade, nodal involvement, surgical margins, and outcome were stratified according to GM. scMCTs lacking dermal invasion, historically associated with a benign clinical course, had a poor prognosis in 10% of cases. cMCTs exhibiting deep subcutaneous involvement included the largest percentage of high-grade tumors (33%), had the highest occurrence of overt nodal metastases (33%), and had the lowest 1-year survival rate (86%). Histologic grade was confirmed as a relevant prognostic factor, surpassing nodal involvement and histologic margin status. The 2-tier histologic grading enabled the identification of all MCTs with aggressive biological behavior, regardless of their cutaneous or subcutaneous location.

3.
Front Vet Sci ; 10: 1279881, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38076567

RESUMEN

Mast cell tumor (MCT) is a common skin cancer in dogs that has a wide range of clinical behaviors. The purpose of this study was to develop a novel multicolor flow cytometry (FC) panel that will enable the quantification of candidate prognostic markers (Ki-67 and pKIT) in fine needle aspirate (FNA) samples prior to surgical removal of the tumors. FNA of canine MCTs and the NI-1 cell line were utilized to develop a FC panel that includes a viability dye (FVS620, BD Biosciences; 7-AAD, Invitrogen) and the following primary conjugated antibodies: CD117-PE (ACK45, BD Biosciences), pKIT-A647 (polyclonal bs-3242R, BIOSS) and Ki-67-FITC (20Raj1, eBioscience; MIB-1, DAKO). A total of nine FNA samples of canine MCTs were collected, seven out which produced sufficient cells for FC analysis. The Ki-67 antibody clone 20Raj1 produced a positive signal when applied to blood leukocytes but failed to provide robust labeling of neoplastic mast cells. The Ki-67 antibody clone MIB-1 delivered a superior staining quality in both the NI-1 cells and primary MCT cells. CD117-PE signal was adequate post fixation and permeabilization and in the combination of 7-AAD. pKIT produced non-specific staining and was not suitable for this multicolor FC panel. In conclusion, FNA samples of canine MCTs can often yield adequate cell numbers for FC analysis, and a multicolor FC panel was developed that can detect Ki-67 in canine mast cells. This would permit further studies into the potential use of this panel for canine cutaneous and subcutaneous MCT prognostication purposes.

4.
Vet Sci ; 10(7)2023 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-37505841

RESUMEN

Several studies evaluating Ki67 in canine cutaneous mast cell tumors (cMCTs) have reported its prognostic value when tumors of all histological grades are included. This study aims to evaluate whether the Ki67 index has a predictive value in a homogeneous cohort of G2/LG cMCTs with HN2 lymph nodes (LNs) and to describe the clinical outcome. The second goal was to explore the correlation between the Ki67 index and MC. The medical databases of three institutions were retrospectively searched for dogs undergoing surgical treatment for cMCT and LN extirpation, with a histological diagnosis of G2/LG with HN2 LNs. Information about histological margins, MC, Ki67 index, local recurrence, nodal relapse, distant metastasis, de novo cMCT occurrence and date and cause of death were included. A total of 39 cases were identified. None of these developed local and nodal relapse or metastatic distant disease. Median MC was 1 (0-2). Median Ki67 index was 3.5 (0.7-14.3). Ki67 and MC were not significantly correlated. At the end of the study, 32 (82%) dogs were alive, 7 (18%) dogs were dead from unrelated causes and 4 (10.2%) dogs were lost to follow-up. The median ST was not reached, and the mean was 893 days (104-2241 days). Considering the strict inclusion criteria, dogs affected by G2/LG with HN2 LNs treated with surgery alone may have a good oncologic outcome; the Ki67 index does not have prognostic impact.

5.
J Vet Med Sci ; 84(2): 208-212, 2022 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-34937843

RESUMEN

This report described the histopathological and immunohistochemical features of cutaneous mast cell tumor (MCT) in six hedgehogs. The hedgehogs presented single cutaneous mass with ulcer and crusting. Histologically, the neoplastic lesions were characterized by the proliferation of well-differentiated mast cells (3 cases), and atypical mast cells (3 cases) with one atypical histiocytic morphology. Immunohistochemically, tumor cells were positive for KIT and mast cell tryptase, and were negative for Iba-1. In well-differentiated MCT, all patients were clinically improved and survived more than 365 days after surgical excision, whereas an atypical histiocytic MCT showed aggressive behavior with re-recurrence, and the animal died 115 days after surgery. These findings suggest that, compatible with other animals, well-differentiated MCT has a better prognosis in hedgehogs.


Asunto(s)
Erizos , Mastocitos , Animales , Macrófagos , Piel
6.
Vet Pathol ; 52(4): 621-30, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25161207

RESUMEN

Canine cutaneous mast cell tumors (MCT) are common, frequently malignant neoplasms that are currently graded histologically for provision of prognostic information. Continuing evidence of subsets of MCT within certain grades (with differing survival times) indicate the need for biomarkers that will facilitate better patient stratification and also provide further information on the biological processes involved in progression. We decided to investigate the expression of p62/sequestosome-1 (p62/SQSTM1), a stress-inducible "hub protein" found in all cell types that shuttles rapidly between the nucleus and cytoplasm and is known to play important roles in protein handling and tumorigenesis. The identity of canine p62/SQSTM1 was confirmed in silico and by validation of a commercial antibody using both Western blotting and functional (pharmaceutical-based) analyses in cell culture. Using immunohistochemistry, 3 patterns of p62 expression were identified based on the predominant intracellular localization, that is, nuclear, mixed (nuclear and cytoplasmic), and cytoplasmic. There was a highly significant association with the 2-tier (Kiupel) grade (P < .0001), with all p62-nuclear immunoreactivity being associated with low grade and most p62-cytoplasmic immunoreactivity (93%) with high grade. Most but not all mixed nuclear-cytoplasmic labeling occurred in low-grade MCT; in other (human) tumor types, this pattern has been interpreted as borderline malignant. These data indicate that there is a shift in protein-handling stress from the nucleus to the cytoplasm in association with increasing malignancy in MCT. Studies to identify the processes and drug-able targets involved in this progression are ongoing.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Enfermedades de los Perros/patología , Mastocitos/patología , Proteína Sequestosoma-1/metabolismo , Neoplasias Cutáneas/veterinaria , Secuencia de Aminoácidos , Animales , Carcinogénesis , Citoplasma/metabolismo , Enfermedades de los Perros/metabolismo , Perros , Inmunohistoquímica/veterinaria , Mastocitos/metabolismo , Pronóstico , Alineación de Secuencia , Proteína Sequestosoma-1/química , Proteína Sequestosoma-1/inmunología , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología
7.
Pesqui. vet. bras ; Pesqui. vet. bras;34(9): 874-884, set. 2014. ilus, tab
Artículo en Portugués | LILACS | ID: lil-728826

RESUMEN

O mastocitoma é a neoplasia cutânea maligna de maior frequência em cães. Apesar do estudo e do desenvolvimento de diversos marcadores prognósticos na tentativa de prever o comportamento biológico deste tipo de neoplasia, a graduação histológica continua sendo utilizada como principal delineador prognóstico para os animais acometidos, mesmo não conseguindo prever o comportamento de mastocitomas de diferenciação intermediária. Diferentes marcadores de proliferação e atividade celular vêm sendo testados com resultados promissores, entretanto, em sua maioria, demandam técnicas específicas de coloração e imuno-histoquímica que, ainda hoje, são de alto custo e muitas vezes não estão facilmente disponíveis. O índice mitótico é um método indireto de mensuração da atividade proliferativa celular, que pode ser contabilizado em uma lâmina comum de avaliação histológica e estudos vêm determinando-o como importante marcador prognóstico para o mastocitoma canino. Dada a recente publicação sugerindo nova graduação em dois graus (alto e baixo) e indisponibilidade das técnicas específicas utilizadas na determinação de outros fatores prognósticos, objetivou-se avaliar o poder prognóstico das diferentes classificações, associando-as à sobrevida destes animais e comparando com o índice mitótico. Apesar de isoladamente ambas as classificações histológicas apresentarem associação com a sobrevida (P<.001) dos animais acometidos, na análise multifatorial nenhuma foi significativamente associada com a sobrevida (P>0,05)...


Mast cell tumor (MCT) is the most common malignant cutaneous neoplasm in dogs. Even with several prognostic markers being studied, in attempt to previse the biological behavior of these tumors, the histological grading is still commonly used to predict behavior, however, it is not significant to predict intermediately differentiated MCT behavior. Different prognostic and cell proliferation markers are being tested with promising results however, the majority of then requires specific staining and immunohistochemical techniques that even nowadays are expensive and not suitable for all veterinarians. Mitotic index is an indirect measure of cell proliferation and it can be established in a common histological microscope slide, and studies indicate it as an important prognostic marker for MCT in dogs. Given the recent publication of the novel two-tier histologic grading system, this study objective to evaluate the prognostic value of the different grading systems associating with survival and compare it with the mitotic index. Even though both grading systems associate with survival in the univariable analyses (P<.001), at the multivariable analyses neither was associated with survival (P>0,05)...


Asunto(s)
Animales , Perros , Enfermedades de los Perros/fisiopatología , Índice Mitótico , Biomarcadores de Tumor , Mastocitoma Cutáneo/veterinaria , Pronóstico , Índice Mitótico/veterinaria , Neoplasias Cutáneas , Sobrevida
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...